tbuckley/cabot-search huggingface dataset:
THE SHRINKING SPECIFICITY OF THE TRANSAMINASE DETERMINATION
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Is Managed Care Really Here to Stay?
Authors: Donald Petroski
Journal: JAMA (1997)

<h3>To the Editor.</h3> —Changes sweeping over medicine involve more the business of delivery than the science of medicine. In his Commentary<sup>1</sup>on managed care, Dr Fuchs<sup>1</sup>underlined concerns that "social gains from greater efficiency" are but a "transfer from one set of pockets to another." I agree with Fuchs that managed care is here to stay, but I disagree with his first of 3 statements on public policy; ie, "only the government can create a system to co ver the uninsured." To prevent the need of state or federal governments to create a tax burden to subsidize health care for the uninsured, health insurance companies should be required to cover a predetermined number of screened, uninsured individuals as part of their obligation of licensure. Managed care companies should take the initiative and prevent legislatures from having to act in the public interest. Changes in the health care system
Pathology and Treatment of Sexual Impotence.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Recombinant Human Erythropoiesis Stimulating Agents in Cancer Patients: Individual Patient Data Meta-Analysis on Behalf of the EPO IPD Meta-Analysis Collaborative Group
Authors: Julia Bohlius, Corinne Brillant, Michael Clarke, Sabine Kluge, Maryann Napoli, Margaret Piper, Dirk Rades, Martin Schumacher, Kurt Schmidlin, Guido Schwarzer, Jerome Seidenfeld, David P. Steensma, Sven Trelle, Olaf Weingart, Marcel Zwahlen, Matthias Egger, Andreas Engert
Journal: Blood (2008)
Lethal Effects of Tannic Acid in the Barium Enema. Report of Three Fatalities and Experimental Studies
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In Reply:
Authors: Judd W. Moul
Journal: Journal of Clinical Oncology (2005)

I was interested to read the report of Carter et al of a conservative management strategy for early prostate cancer, 1 and I agree with the authors that the term "watchful waiting" does not accurately describe their strategy.Given the overdiagnosis and lead-time bias associated with prostate-specific antigen (PSA) screening, 2 the natural history of prostate cancer following diagnosis is now far more favorable than it was in the pre-PSA era, making a conservative management strategy an attractive option for many patients.However, clinicians and patients need to understand the important distinctions between the different conservative strategies now available.The term watchful waiting was widely used during the pre-PSA era to describe a policy of observation with palliative treatment for symptomatic cancer progression.Such a policy remains appropriate for patients who, by virtue of age and comorbidities, have a relatively short life expectancy and do not have a radical treatment option.A second, and quite distinct, approach to favorable-risk early prostate cancer is to determine the need for radical treatment based on biochemical or histologic evidence of disease progression during close monitoring.The aim of this approach is to target curative treatment to the minority of patients who need it, so that the majority are spared the side effects of unnecessary treatment.This strategy was first described by Richard Choo et al as, "watchful observation with selective delayed intervention." 3At the Royal Marsden Hospital, we use the term "active surveillance" to describe this strategy. 4 These initial studies have demonstrated the feasibility of this approach, which offers patients a realistic hope of avoiding treatment side effects without detriment to their survival.Active surveillance requires a clear definition of the indications for radical treatment (usually based on PSA doubling time and the results of repeat biopsies), together with a commitment to the policy from both patient and clinician.If these are lacking, the result will be "temporarily deferred therapy," as described by Carter et al, in which men with early prostate cancer who are almost inevitably going to have radical treatment, choose to delay such therapy. 1
DIPG-26. THERAPEUTIC EFFECTS OF RADIOTHERAPY WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE VERSUS RADIOTHERAPY WITH CONCOMITANT TEMOZOLOMIDE ALONE IN CHILDREN WITH DIPG: A SINGLE-CENTER EXPERIENCE WITH 82 CASES
Authors: Mingyao Lai, Juan Li, Qingjun Hu, Jiangfen Zhou, Shaoqun Li, Lei Wen, Zhaoming Zhou, Cheng Zhou, Lichao Wang, Changguo Shan, Yangqiong Zhang, Rishun Luo, Linbo Cai
Journal: Neuro-Oncology (2020)

Abstract OBJECTIVE To retrospectively analyze the therapeutic effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy with concomitant temozolomide alone for pediatric diffuse intrinsic pontine glioma (DIPG), and to evaluate the value of temozolomide in the treatment of pediatric DIPG. METHODS The clinical data of children with confirmed DIPG in Guangdong Sanjiu Brain Hospital between January 1, 2010 and December 30, 2019 were collected. The inclusive criteria included (1) receiving a total radiotherapy dose of 54 Gy in 27 fractions, (2) treated with concomitant temozolomide chemotherapy, and (3) with or without adjuvant temozolomide chemotherapy. RESULTS A total of 82 pediatric patients were eligible for the study, with a median age of 7 years (range 2–16 years). The median follow-up was 8.6 months (range 2–28 months) and the median survival time was 9.4 months. The median survival time of 66 patients treated with radiotherapy with concomitant and adjuvant temozolomide was 9.8 months, longer than 7.5 months of the other 16 patients treated with radiotherapy with concomitant temozolomide alone, with statistical differences (P=0.010). Moreover, bevacizumab and nimotuzumab didn’t bring survival benefits to patients with disease recurrence or progression. Hematological toxicity (Grade IV) was not found. CONCLUSION Radiotherapy with concomitant and adjuvant temozolomide prolongs the survival time of children with DIPG.
PWE-043 Screening for enteric infection in inflammatory bowel disease patients contacting the ibd helpline and presenting with disease flares
Authors: HE Johnson, K Wade, S Weaver, S McLaughlin
Journal: Gut (2015)

<h3>Introduction</h3> We participated in the UK National Audit of inflammatory bowel disease service provision (Royal College of physicians, 2014). This recommends that &gt;90% of inflammatory bowel disease (IBD) patients with diarrhoea, have a stool sample sent for culture and Clostridium difficile (CDT) testing on admission. ECCO guidelines recommend stool testing in both outpatient and inpatient disease flares. To date a national audit reviewing stool testing of patients contacting IBD Helplines for advice with diarrhoea has not been performed; therefore we reviewed the results from our clinical practice of both inpatients and out-patients. <h3>Method</h3> We searched the IBD telephone helpline electronic records from September 2011 to October 2014 to identify patients presenting with diarrhoea. Electronic records were reviewed to determine if stool samples for standard stool culture and CDT were requested before escalating therapy, and the results of that testing. By searching hospital admission data we identified all patients admitted for &gt;24 h with a diagnosis of Crohn–s disease or ulcerative colitis with symptoms of loose stool and increased frequency during the same time period and reviewed the same data. <h3>Results</h3> 357 patients contacted the IBD Helpline complaining of diarrhoea. 357 (100%) were sent stool pots for standard stool culture and CDT by post. Results were reviewed before deciding on further management. 300 (84%) patients completed the tests. Of these 15 (5%) were positive. 8 showed CDT, 6 Campylobacter and 1 Blastocystis hominis. 179 (99 male) IBD patients were admitted during the same 3 year period with symptoms of a flare. 122 patients had diarrhoea on admission. 96 (79%) underwent stool testing. 2 (2%) were positive for infection: 1 for campylobacter, 1 for CDT. <h3>Conclusion</h3> These results demonstrate that enteric infection is a relatively common cause of disease flares and underlines the importance of screening for this. Unfortunately frequency of stool testing in our inpatient population falls below recommended standards. In contrast testing undertaken by our nurse-led IBD helpline met the standard. <h3>Disclosure of interest</h3> H. Johnson: None Declared, K. Wade Conflict with: sponsorship from Abbvie, S. Weaver Conflict with: Advisory board for MSD and Abbvie, S. McLaughlin Conflict with: Sponsorship from Abbvie and Ferring to attend international meetings.
Competency as Evidence of Statements Made to Physicians.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3203: Intratumoral STING activation normalizes tumor vasculatures and synergizes with anti-angiogenic therapy to enhance cancer immunity
Authors: Hannah Yang, Hyojoong Kim, Joo Hoon Kim, Hong Jae Chon, Chan Kim
Journal: Cancer Research (2019)

Abstract Purpose: The stimulator of interferon genes (STING) signaling pathway is a critical link between innate and adaptive immunity, and induces anti-tumor immune responses. STING is expressed in vasculatures, but its role in tumor angiogenesis has not been elucidated. Here we investigated STING-induced tumor vascular remodeling and the potential of STING-based combination immunotherapy. Experimental Design: We examined the endothelial STING expression pattern and clinical implications in human malignancies. STING-induced vascular remodeling was studied using STING-deficient or wild-type mice. Implanted LLC tumors and transgenic MMTV-PyMT breast tumors were intratumorally injected with STING agonists (cGAMP or RR-CDA), with or without anti-VEGFR2 antibody and/or immune checkpoint inhibitors. The tumor microenvironment was evaluated by histologic and immune profiling analyses. Results: Endothelial STING expression was correlated with enhanced T-cell infiltration, reduced lymphovascular invasion, and prolonged survival in human colon and breast cancer. Intratumoral STING activation normalized tumor vasculatures, as shown by increased pericyte coverage and intact basement membrane, which was mediated by upregulation of vascular stabilizing genes (e.g., Angpt1, Pdgfrb, and Col4a) and endothelial-lymphocyte interaction genes. These effects were dependent on type I interferon signaling and CD8+ T cells. STING activation also induced M1-like macrophage polarization within tumors. Notably, STING-based immunotherapy was maximally effective when combined with VEGFR2 blockade and/or immune checkpoint blockade (αPD-1 or αCTLA-4), leading to complete regression of immunotherapy-resistant tumors. Conclusions: Our data show that intratumoral STING activation can normalize tumor vasculature and the tumor microenvironment, providing a rationale for combining STING-based immunotherapy and anti-angiogenic therapy. Citation Format: Hannah Yang, Hyojoong Kim, Joo Hoon Kim, Hong Jae Chon, Chan Kim. Intratumoral STING activation normalizes tumor vasculatures and synergizes with anti-angiogenic therapy to enhance cancer immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3203.
Radiotherapeutic principles and viewpoints
Authors: I. Lampe
Journal: JAMA (1971)

Squamous cell carcinoma is an important and common cancer of the oral cavity and the lower lip. Although variable degrees of differentiation do occur, the predominant histopathological finding is in the direction of a moderate to a well-differeniated tumor. On the lower lip, in the oral cavity (in which the common location is the oral portion of the tongue), the floor of the mouth, and the lower gingiva (mandible), the squamous cell carcinoma is a radioresponsive and radiocurable neoplasm. The therapeutic armamentarium currently available for attack on these lesions is diverse; it includes radiations uniquely advantageous for obtaining control of these tumors. They range from low-voltage x-ray suitable for superficial lip carcinomas, to orthovoltage radiation for advanced lip lesions and per oral techniques, to supervoltage radiation; the latter minimizes acute and chronic cutaneous radiation reactions and, significantly, relatively spares the bone tissues. In addition, low-intensity radium needles or radioactive substitutes
The Medical Aspects of the Modern “Sky Scraper”
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Harvey Lectures, delivered under the auspices of the Harvey Society of New York, 1961-62. Series 57.
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Radiation Therapy
Authors: Carlos A. Perez
Journal: JAMA (1967)

This new edition, like the first edition, reflects the author's vast experience in the management of cancer and the use of orthovoltage irradiation. Except for the change to the double column, the format of the book and most of the material presented are essentially the same as in the first edition. Dr. Murphy summarizes the clinical and pathological features of every group of tumors in each region of the body and analyzes the indications for different treatment methods. The practical aspects of irradiation are described in detail in terms of energy of the beam, port arrangements, and technical factors. The latter are unnecessarily over-emphasized, at a time in which orthovoltage units are progressively becoming obsolete (except for superficial therapy) and are being replaced by supervoltage equipment. The dose schedules conform, in most instances, to modern concepts of supervoltage irradiation. The clinical illustrations are excellent. The drawings of portals and summation
Percutaneous transluminal angioplasty.Council on Scientific Affairs
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
'Lactate washout' following circulatory arrest
Authors: J A Leavy, M H Weil, E C Rackow
Journal: JAMA (1988)

The measurement of arterial blood lactate concentration for the purpose of estimating the severity and prognosis of acute perfusion failure is suspect because of theoretical errors due to systemic "lactate washout" immediately following restoration of perfusion. If arterial lactate concentrations continue to increase following resuscitation, the assumption that increasing lactate concentrations indicate progression of anaerobiosis due to perfusion failure would be invalidated. Lactate washout was therefore investigated in a porcine model of cardiac arrest due to electromechanical dissociation. Cardiopulmonary resuscitation was initiated and maintained for intervals of 30 minutes or until spontaneous circulation was restored. In 25 trials on 14 successfully resuscitated animals, the arterial blood lactate concentration decreased within four minutes after resuscitation from cardiac arrest. In 24 animals in whom resuscitation efforts failed, arterial lactate concentrations increased throughout the observation period. Lactate washout occurred during an interval of only 2.6 ±0.3 minutes (mean ± SEM). These results indicate that lactate measurements are not invalidated because of a washout phenomenon under the extreme conditions of cardiac arrest. (<i>JAMA</i>1988;260:662-664)